These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 28620891

  • 1. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
    Mo G, Baldwin JR, Luffer-Atlas D, Ilaria RL, Conti I, Heathman M, Cronier DM.
    Clin Pharmacokinet; 2018 Mar; 57(3):355-365. PubMed ID: 28620891
    [Abstract] [Full Text] [Related]

  • 2. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R, Conti I, Cosaert J, Schwartz GK.
    Lancet; 2016 Jul 30; 388(10043):488-97. PubMed ID: 27291997
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.
    Villalobos VM, Mo G, Agulnik M, Pollack SM, Rushing DA, Singh A, Van Tine BA, McNaughton R, Decker RL, Zhang W, Shahir A, Cronier DM.
    Cancer Med; 2020 Feb 30; 9(3):882-893. PubMed ID: 31821732
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma.
    Yonemori K, Kodaira M, Satoh T, Kudo T, Takahashi S, Nakano K, Ando Y, Shimokata T, Mori J, Inoue K, Oakley GJ, Sakaguchi S, Tamura K.
    Cancer Sci; 2018 Dec 30; 109(12):3962-3970. PubMed ID: 30353601
    [Abstract] [Full Text] [Related]

  • 7. Olaratumab for the treatment of advanced soft tissue sarcoma.
    Okuno SH, Maran A, Robinson SI.
    Expert Rev Anticancer Ther; 2017 Oct 30; 17(10):883-887. PubMed ID: 28862476
    [Abstract] [Full Text] [Related]

  • 8. Olaratumab for advanced soft tissue sarcoma.
    Tobias A, O'brien MP, Agulnik M.
    Expert Rev Clin Pharmacol; 2017 Jul 30; 10(7):699-705. PubMed ID: 28447475
    [Abstract] [Full Text] [Related]

  • 9. Olaratumab in the management of advanced soft tissue sarcoma.
    Zobniw CM, Trinh VA, Posey K, Somaiah N.
    J Oncol Pharm Pract; 2019 Mar 30; 25(2):442-448. PubMed ID: 30032714
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.
    Andrick BJ, Gandhi A.
    Ann Pharmacother; 2017 Dec 30; 51(12):1090-1098. PubMed ID: 28778132
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
    Tap WD, Wagner AJ, Schöffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, Yen CC, Abdul Razak AR, Spira A, Kawai A, Le Cesne A, Van Tine BA, Naito Y, Park SH, Fedenko A, Pápai Z, Soldatenkova V, Shahir A, Mo G, Wright J, Jones RL, ANNOUNCE Investigators.
    JAMA; 2020 Apr 07; 323(13):1266-1276. PubMed ID: 32259228
    [Abstract] [Full Text] [Related]

  • 16. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
    Mascarenhas L, Ogawa C, Laetsch TW, Weigel BJ, Bishop MW, Krystal J, Borinstein SC, Slotkin EK, Muscal JA, Hingorani P, Levy DE, Mo G, Shahir A, Wright J, DuBois SG.
    Cancer Med; 2021 Feb 07; 10(3):843-856. PubMed ID: 33474828
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S, Jansen M, Matsushima N, Chen S, Mendell J.
    Cancer Chemother Pharmacol; 2016 May 07; 77(5):987-96. PubMed ID: 27017616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.